Urology最新文献 - Book学术

Reply to Editorial Comment on "Post-procedural Urethral Strictures After Aquablation".

IF 2 3区医学

Urology Pub Date : 2025-10-05 DOI: 10.1016/j.urology.2025.10.006

Jessica Pryor, Samuel Ivan, Jay Simhan, Steven Sterious

引用次数: 0

Reliability of Prostate Imaging-Reporting and Data System (PIRADS) Scoring Following Holmium Laser Enucleation of Prostate (HoLEP). 钬激光前列腺摘除（HoLEP）后前列腺影像报告和数据系统（PIRADS）评分的可靠性。

IF 2 3区医学

Urology Pub Date : 2025-10-03 DOI: 10.1016/j.urology.2025.09.045

Benjamin N Schmeusser, Jason L Zappia, Kyle R Edwards, Kate H Adaniya, Justin K Kim, Kevin R Rice, Ronald S Boris, Marcelino E Rivera, Thomas M Shelton

{"title":"Reliability of Prostate Imaging-Reporting and Data System (PIRADS) Scoring Following Holmium Laser Enucleation of Prostate (HoLEP).","authors":"Benjamin N Schmeusser, Jason L Zappia, Kyle R Edwards, Kate H Adaniya, Justin K Kim, Kevin R Rice, Ronald S Boris, Marcelino E Rivera, Thomas M Shelton","doi":"10.1016/j.urology.2025.09.045","DOIUrl":"https://doi.org/10.1016/j.urology.2025.09.045","url":null,"abstract":"Objective: To determine whether prostate MRI PI-RADS scoring following HoLEP can reliably predict detection of prostate cancer on prostate biopsy.Methods: Patients who underwent HoLEP followed by prostate MRI, targeted prostate biopsy, and systematic biopsy at a single institution from 2012 to 2024 were retrospectively reviewed. Patients were grouped based on highest PI-RADS score noted on prostate MRI. Patient demographics and clinical characteristics were gathered, and multivariate analyses were performed. Prevalence of prostate cancer detection based on PIRADS score were calculated. Locations of PIRADS lesions were also documented.Results: 44 patients who underwent HoLEP followed by prostate MRI and targeted biopsy were included in our analysis. In post-HoLEP patients with PI-RADS lesions of 3, 4 or 5, clinically significant prostate cancer was detected in 66.7%, 59%, and 100% of patients on biopsy, respectively. 83% (n=5) of patients with PI-RADS 1-2 lesions were found to have clinically significant prostate cancer on systematic biopsy.Conclusions: Prostate MRI and the PI-RADS system to detect prostate cancer does appear to have utility in patients that underwent HoLEP. A high proportion of patients with low PI-RADS scores were found to have clinically significant prostate cancer on systematic biopsy, however, therefore PI-RADS scoring alone should not impact a clinician's decision of whether to perform prostate biopsy. Additional characteristics such as PSA, PSA density or PSA kinetics should also be considered when determining when to perform prostate biopsy in post HoLEP patients.","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial Comment on "Impact of GLP-1 Receptor Agonists on Male Fertility: Emerging Evidence and Future Directions". 《GLP-1受体激动剂对男性生育能力的影响：新证据和未来方向》的社论评论。

IF 2 3区医学

Urology Pub Date : 2025-10-03 DOI: 10.1016/j.urology.2025.09.046

Sevann Helo

引用次数: 0

Patient-Centered Priorities in Prostate Cancer Survivorship Care. 前列腺癌生存护理中以患者为中心的优先事项。

IF 2 3区医学

Urology Pub Date : 2025-10-02 DOI: 10.1016/j.urology.2025.09.048

Delaney J Orcutt, Leah Chisholm, Elizabeth Winkler, Melissa R Kaufman, Daniel A Barocas, Kerry R Schaffer, Niels V Johnsen

{"title":"Patient-Centered Priorities in Prostate Cancer Survivorship Care.","authors":"Delaney J Orcutt, Leah Chisholm, Elizabeth Winkler, Melissa R Kaufman, Daniel A Barocas, Kerry R Schaffer, Niels V Johnsen","doi":"10.1016/j.urology.2025.09.048","DOIUrl":"https://doi.org/10.1016/j.urology.2025.09.048","url":null,"abstract":"Objectives: To assess patient priorities after prostate cancer treatment to guide patient-centered survivorship clinic design and care delivery.Methods: Adapted, preexisting validated questionnaires were used to assess survivorship care priorities among prostate cancer survivors at our institution. Participants ranked aspects of follow-up care across 5 domains and identified all items they considered important aspects of prostate cancer survivorship care from 27 listed components. Importance of priorities was determined by ranking frequency of selections and then compared based on treatment modality.Results: Of 362 responders, 259 (71.5%) had surgery and 103 (28.5%) had radiation. Survivors prioritized screening for recurrence and additional malignancies, general health screening, management of urinary and sexual side effects, and receiving care through an integrated health system. They also appreciated being well-informed about tests being conducted, as well as understanding the benefits and potential side effects of treatments before making decisions. More surgery patients felt management of sexual side effects was important, and more radiation patients valued management of bowel side effects and clinic accessibility. Less frequently prioritized components included support groups, minimizing time away from other responsibilities, and smoking cessation counseling.Conclusions: Patient-centered research in prostate cancer survivorship helps tailor care to patient priorities, which may vary based on treatment modality. Incorporating patient priorities into clinic design may boost satisfaction, participation, and quality of life while reducing the burdens of survivorship after treatment.","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Post Void Residual and Bladder Capacity Predict Urinary Continence Following Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia". 良性前列腺增生钬激光摘除前列腺后膀胱容量和空腔残留预测尿失禁。

IF 2 3区医学

Urology Pub Date : 2025-10-02 DOI: 10.1016/j.urology.2025.09.049

Feres C Maluf, William A Pace, Lynn Leng, Pablo Suarez, Darren Chau, Udaybir Mann, Maria C Velasquez, Kazumi Taguchi, Joel T Funk, James E Bryant, Karishma Gupta, Thomas Chi

{"title":"\"Post Void Residual and Bladder Capacity Predict Urinary Continence Following Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia\".","authors":"Feres C Maluf, William A Pace, Lynn Leng, Pablo Suarez, Darren Chau, Udaybir Mann, Maria C Velasquez, Kazumi Taguchi, Joel T Funk, James E Bryant, Karishma Gupta, Thomas Chi","doi":"10.1016/j.urology.2025.09.049","DOIUrl":"https://doi.org/10.1016/j.urology.2025.09.049","url":null,"abstract":"Objectives: To better understand and potentially predict transient urinary incontinence (TUI) following Holmium laser enucleation of the prostate (HoLEP), we investigated whether preoperative urodynamic studies (UDS), the gold standard for assessing bladder physiology, can identify patients at higher risk for TUI.Methods: We conducted a single-institution retrospective cohort study of patients who underwent UDS followed by HoLEP for BPH between 2017 and 2023. We collected data on baseline characteristics, UDS parameters, and perioperative outcomes. The primary outcome was urinary incontinence (UI) at 1, 3, 6, and 12 months post-surgery.Results: 129 subjects were identified and univariate analysis demonstrated that post-operative UI rates were lower in patients with a preoperative post-void residual (PVR) greater than 250mL when compared to those with a PVR ≤250mL at 3 months (33.3% vs. 55.6%;p=0.02) and 6 months (11.5% vs. 39.2%;p<0.01). Similarly, patients with a bladder capacity exceeding 600mL experienced lower UI rates at 1 month (p=0.01), 6 months (p<0.01), and 12 months (p=0.03) compared to those with a bladder capacity ≤600mL. Furthermore, adjusted analysis confirmed these findings that PVR >250mL and bladder capacity >600mL were associated with a 28% (95%CI [12.1%-43.3%];p<0.01) and 26% (95%CI [13.2%-39%];p<0.01) lower probability of UI at 6 months, respectively.Conclusions: Adding baseline PVR and bladder capacity assessment to the preoperative evaluation may supplement counseling on protective factors for UI following HoLEP.","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The 2025 Urology Match: Results From the Society of Academic Urologists Program Director Survey. 2025泌尿科匹配：来自学术泌尿科医师协会项目主任调查的结果。

IF 2 3区医学

Urology Pub Date : 2025-10-01 DOI: 10.1016/j.urology.2025.09.043

Srinath-Reddi Pingle, Michael Creswell, Sarah Faris, Kirsten Greene, Christopher Keel, Lee Richstone, Mathew Sorensen, Simone Thavaseelan, Erica Traxel, Moben Mirza, Gina M Badalato

{"title":"The 2025 Urology Match: Results From the Society of Academic Urologists Program Director Survey.","authors":"Srinath-Reddi Pingle, Michael Creswell, Sarah Faris, Kirsten Greene, Christopher Keel, Lee Richstone, Mathew Sorensen, Simone Thavaseelan, Erica Traxel, Moben Mirza, Gina M Badalato","doi":"10.1016/j.urology.2025.09.043","DOIUrl":"https://doi.org/10.1016/j.urology.2025.09.043","url":null,"abstract":"Objectives: To provide a comprehensive overview of the 2025 SAU program directors (PD) survey and their perspectives on key aspects of the SAU Urology Match.Methods: A survey consisting of 43 questions designed and distributed by the SAU was sent to all PDs in the 2025 SAU Urology Match. Descriptive analyses were performed on the responses, and qualitative themes were extracted from free-text answers.Results: 104 (61%) of PDs completed at least one survey question. In terms of interview modality, 43% offered virtual-only, 23% hybrid, and 34% in person-only. Cost was a key reason among those programs offering virtual/ hybrid formats, and applicant assessment was a main factor for programs offering the in-person option. A quarter of programs hosting in-person interviews provided hotel accommodations to mitigate applicant costs. Programs cited a lack of funding or institutional policies as factors in not providing financial incentives. Preference signals were used as a screening tool before application review by 76% of PDs, and 46% incorporated signals into the initial application review.Conclusion: The results provide a comprehensive overview of program directors' views on recent changes to the SAU Urology Match. The findings reveal variations in interview formats and the use of preference signaling, along with growing concerns about the financial burden linked to in-person interviews. These insights are valuable for informing future improvements to the SAU Urology Match.","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145226103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Artificial Urinary Sphincter Improves Emotional Health in Men with Stress Urinary Incontinence: Results from the Prospective, Multi-institutional AUSCO Study. 人工尿括约肌改善压力性尿失禁男性的情绪健康：来自前瞻性、多机构的AUSCO研究的结果

IF 2 3区医学

Urology Pub Date : 2025-10-01 DOI: 10.1016/j.urology.2025.09.037

Andrew C Peterson, Hadley M Wood, Jeremy Myers, Benjamin N Breyer, Bradley A Erickson, Thomas G Smith Iii, Erin L Chaussee, Melissa R Kaufman, Ryan Terlecki, Niels V Johnsen, Alex J Vanni, Daniel Moon, LeRoy Jones, Joshua A Broghammer, Gerard Henry, Arthur L Burnett, Lewis Wen Loong Chan, Brian J Flynn, Rose Khavari, Sean Elliott

{"title":"The Artificial Urinary Sphincter Improves Emotional Health in Men with Stress Urinary Incontinence: Results from the Prospective, Multi-institutional AUSCO Study.","authors":"Andrew C Peterson, Hadley M Wood, Jeremy Myers, Benjamin N Breyer, Bradley A Erickson, Thomas G Smith Iii, Erin L Chaussee, Melissa R Kaufman, Ryan Terlecki, Niels V Johnsen, Alex J Vanni, Daniel Moon, LeRoy Jones, Joshua A Broghammer, Gerard Henry, Arthur L Burnett, Lewis Wen Loong Chan, Brian J Flynn, Rose Khavari, Sean Elliott","doi":"10.1016/j.urology.2025.09.037","DOIUrl":"https://doi.org/10.1016/j.urology.2025.09.037","url":null,"abstract":"Objective: To examine the effects on depression, anxiety and overall emotional health in patients undergoing artificial urinary sphincter (AUS) surgery for stress urinary incontinence (SUI). Few reports focus on the impact of AUS implantation on emotional health in men with SUI.Methods: The Artificial Urinary Sphincter Clinical Outcomes Trial (AUSCO) was a prospective, single-arm, multi-site study designed to evaluate outcomes in men with SUI treated with the AMS 800™ AUS (NCT04088331). A total of 115 subjects were implanted. Follow-up assessments at 3-, 6-, and 12-months post device activation were compared to baseline. These analyses focus on emotional health, measured with the Incontinence QOL (I-QOL), Incontinence Impact Questionnaire (IIQ-7), and EQ-5D-5L.Results: At 12 months, 100 had completed QOL assessments. Depression rating (Item 5, I-QOL) significantly improved, with 85% (85/100) of patients reporting feeling at least \"a little\" depressed at baseline decreasing to 39% (39/100) at 12 months (p<0.0001). Emotional health rating (Item 6, IIQ-7) also improved, with 16% (16/100) reporting being \"greatly\" affected by incontinence at baseline decreasing to 3% (3/100) at 12 months (p<0.0001). The anxiety/depression domain on the EQ-5D-5L (Item 5) was also significantly improved, with 50% (50/100) of patients reporting being at least \"slightly\" anxious or depressed at baseline decreasing to 30% (30/100) at 12 months (p = <0.0001).Conclusions: These data demonstrate that treatment of SUI with the AUS improves emotional health in men with SUI.","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145226125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel application of Decipher testing in HoLEP specimens for risk stratification of incidentally detected prostate cancer. 在偶然发现前列腺癌的HoLEP标本中进行风险分层的新应用破译测试。

IF 2 3区医学

Urology Pub Date : 2025-10-01 DOI: 10.1016/j.urology.2025.09.047

Nicole Handa, Harsha Kaul, Clayton Neill, James A Proudfoot, Ridwan Alam, Mitchell M Huang, Elai Davicioni, Edward M Schaeffer, Amy E Krambeck, Ashley E Ross

{"title":"A novel application of Decipher testing in HoLEP specimens for risk stratification of incidentally detected prostate cancer.","authors":"Nicole Handa, Harsha Kaul, Clayton Neill, James A Proudfoot, Ridwan Alam, Mitchell M Huang, Elai Davicioni, Edward M Schaeffer, Amy E Krambeck, Ashley E Ross","doi":"10.1016/j.urology.2025.09.047","DOIUrl":"https://doi.org/10.1016/j.urology.2025.09.047","url":null,"abstract":"Objectives: To assess the feasibility of Decipher testing for prostate cancer incidentally identified on specimens from holmium laser enucleation of the prostate (HoLEP). Additionally, we sought to review Decipher GRID expression signatures in cancers identified on HoLEP compared to those identified on prostate biopsy.Methods: We identified patients who had prostate cancer on HoLEP at our institution from August 2021-July 2024 and subsequently underwent Decipher testing. Quality assurance testing was performed and transcriptomic signature expression patterns between HoLEP specimens and Grade Group (GG)-matched biopsy specimens were compared using standard mean differences (SMD).Results: Of the 38 HoLEP specimens that underwent Decipher testing, 2 (5.3%) failed quality assurance testing due to lack of sufficient tumor present in the sample. Compared to GG-matched biopsy specimens (N=58,500), the HoLEP group (N=36) had similar median Decipher scores (0.56 vs 0.45, SMD 0.33) and lower median PSA (3.1 vs 6.2). HoLEP specimens were enriched for lower androgen receptor activity (SMD 0.63), basal subtypes by both PAM50 (SMD 1.23) and PSC (SMD 1.09), and ERG negative status (SMD 0.86). HoLEP specimens also had higher expression of activated CD4 (SMD 1.06), tertiary lymphoid structure (SMD 1.40), and angiogenesis (SMD 1.27).Conclusion: Decipher testing for HoLEP specimens is feasible, although clinical utility remains unclear. Compared to biopsy specimens, HoLEP specimens have increased immune and angiogenesis-related signature expression and lower AR-A expression suggesting that these tumors have unique microenvironments.","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145226116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing Clinical Utility in Randomized Trials of Radical Prostatectomy for Urologic Oncology: An Original Article of Studies Published Between 2020 and 2024. 评估泌尿肿瘤根治性前列腺切除术随机试验的临床效用：一篇发表于2020年至2024年间的原始研究文章。

IF 2 3区医学

Urology Pub Date : 2025-09-30 DOI: 10.1016/j.urology.2025.09.041

Derrick Pruitt, Pau Von, Taylor Gardner, Eli Paul, Alec Young, Reece Anderson, Adam Khan, Chance Bratten, Alicia Ito Ford, Matt Vassar

{"title":"Assessing Clinical Utility in Randomized Trials of Radical Prostatectomy for Urologic Oncology: An Original Article of Studies Published Between 2020 and 2024.","authors":"Derrick Pruitt, Pau Von, Taylor Gardner, Eli Paul, Alec Young, Reece Anderson, Adam Khan, Chance Bratten, Alicia Ito Ford, Matt Vassar","doi":"10.1016/j.urology.2025.09.041","DOIUrl":"https://doi.org/10.1016/j.urology.2025.09.041","url":null,"abstract":"Objective: To assess the clinical usefulness and transparency of randomized controlled trials evaluating radical prostatectomy, given concerns about limited generalizability, transparency, and patient-centered outcomes in surgical research.Methods: We systematically reviewed 40 RCTs published between 2020 and 2024, evaluating RP for prostate cancer. Trials were assessed using the van 't Hooft framework, which includes seven clinical utility and six transparency criteria. Values were analyzed descriptively and by year, with correlation analyses assessing the relationship between transparency and clinical utility.Results: Most trials addressed high-impact clinical questions and included patient-centered outcomes, but only 7.5% met full criteria for pragmatic design, and none fully assessed value for money. Protocol transparency and data sharing were limited. A strong positive correlation was observed between transparency and clinical utility (r = 0.74, p < 0.001). Limitations include potential subjectivity in evaluating and exclusion of unpublished or non-English RCTs.Conclusions: Despite progress in patient-centeredness and reporting of conflicts and funding, RP trials often fall short in pragmatic design and transparency. Greater adherence to reporting standards and inclusion of economic and real-world relevance are essential for maximizing trial impact in urologic oncology.","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to Point-Counterpoint: Compensation for Parental Leave Coverage. 对点对点：育儿假补偿的回复。

IF 2 3区医学

Urology Pub Date : 2025-09-29 DOI: 10.1016/j.urology.2025.09.040

Sameer Farooq, Sydney Sudderth, Harsha Mirchandani, Akanksha Mehta

引用次数: 0